CDx news

---

NGS vs Sanger-based HLA typing for Companion Diagnostics: key differences and clinical implications

Published on April 23, 2026

While still emerging in clinical practice, HLA-restricted therapies are gaining traction in clinical research and early-stage precision medicine applications (see […]

Read more

---

The role of HLA in immunotherapy development

Published on March 26, 2026

Human Leukocyte Antigen (HLA) proteins have long been central in the transplantation field, because of their critical role on transplant […]

Read more

---

GenDx and Treos Bio Announce Partnership to develop HLA-based Companion Diagnostic for PolyPEPI1018 Cancer Immunotherapy

Published on March 17, 2026

PRESS RELEASE Utrecht and London, 17 March 2026 GenDx, a Eurobio Scientific Company, based in the Netherlands, specialized in molecular […]

Read more

---

Navigating Grey Zones & Growing Pains: Developments in the Regulatory CDx Space

Published on March 16, 2026

𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗳𝗼𝗿 𝗼𝘂𝗿 𝗻𝗲𝘄 𝘄𝗲𝗯𝗶𝗻𝗮𝗿! During this webinar, Kirsten van Garsse (QbD Group) and Jules Petit will discuss key elements of our joint panel […]

Read more

---

Supporting Precision Medicine: Our Companion Diagnostics (CDx) services

Published on February 19, 2026

We are excited to share that GenDx updated its website to better showcase our comprehensive Companion Diagnostics (CDx) services. Our […]

Read more

---

GenDx Announces a Collaboration Agreement with OSE Immunotherapeutics

Published on November 21, 2023

PRESS RELEASE Utrecht, 21 November 2023 During the opening of their new offices GenDx Announces a Collaboration Agreement with OSE […]

Read more